Okay, there’s nothing official about it, but the whole world is in a weird time of transition right now – and probably will be for a while. Unlike the jump into the pandemic, or even the a rise of vaccines full of suspense, this time is more optimistic, less frantic, but also stretched in an uneven mess. Places, populations and even industries change at different rates as they return to a semblance of normalcy.
It’s like the whole world is playing with a kinky version of “Yes and.” Yes, more people are vaccinated in the United States than ever before, and immunocompromised people are still in danger. Yes, the vaccines we have are incredibly effective, and they are so rare that many countries are absolutely desperate to get them.
Here in the United States, one of the most visible transitions is the act of disappearance of various COVID-19 regulations. New York lifted most restrictions this week, and Disneyland reopened to all, without mask requirement. Residents of these areas are enjoying a return to offices, restaurants and blessed normality, especially in areas with low case rates. At the same time, parts of the country where immunization rates have remained low are facing the potential for summer surges. Tensions between different regions will persist as long as disparities persist.
In pharmaceutical and research, there is a different change. The wave of clinical trials and laboratory work that accompanied vaccine development is now slowing. There are still thousands of questions, but the biggest and most urgent: can we make a vaccine? – received a response. Today, the lines of research have shifted and divided. Some are still working on vaccines and boosters, others are studying new COVID-19 Drugs or seeking to understand the origins and mechanics of the virus, and others have reverted entirely to different projects. With vaccines, the biggest issues now are surveillance and distribution, not research and development.
What people think of all of these changes is a whole different factor – personal shifts in priorities, fears and emotions are going to play a huge role in this next phase of the pandemic. As vaccinations increase and the number of cases decrease, we will eventually get used to the coronavirus, and it stop being an unknown threat. We will stop thinking about it every day – some people have already done so.
In the meantime, most people are stuck somewhere between caution and surrender. Each person will eventually go beyond their own personal marker for the pandemic era. It can happen when they get that second hit or walk into a theater for the first time or leave a mask sitting on the table at home. As with all transitions, something will end and something else will take its place.
As a quick note before I get into what happened with COVID-19 this week, I also wanted to note that you might see some new (small) changes in this newsletter. Finally, we will move the newsletter to a weekday instead of a Saturday. And from next week, I’ll hand over the reins to Nicole Wetsman, The edgehealth reporter. She replaces regularly, but I’m delighted that she writes to you more regularly.
Some things will not change, at least not yet. We will continue to cover the pandemic and keep you posted on what is happening around the world.
Thank you very much for joining us every week.
In the United States, there is more evidence that vaccines are extremely effective. Doctors and health systems are increasingly reporting that COVID-19 patients presenting for treatment are not vaccinated. (Elizabeth Weise and Aleszu Bajak /USA today)
A study released this week found that one of the reasons for the horrific disparities in deaths from COVID-19 in the United States may come down to a lack of health care resources in hospitals that serve black patients. (Stephanie M Lee /BuzzFeed News)
Another mRNA vaccine has just completed a clinical trial, showing only 47% effectiveness against the virus. This is a setback for the vaccine, which some hoped would help boost the global supply. (Ludwig Burger / Reuters)
A look at the company’s race to produce its new vaccine on an unprecedented scale. (Christophe Rowland /The Washington Post)
$ 3 billion has now been set aside to help researchers get started on treatment for COVID-19. Instead of a vaccine, which prevents the virus from setting in, treatment would fight the disease when a person actually has it. (Carl Zimmer /The New York Times)
Accredited social health activists are the foot soldiers of India’s rural health system. Lately, they have also taken on the daunting task of tackling disinformation about COVID-19, mostly in local WhatsApp groups. Take a look at their efforts to break down the disinformation in their villages. (Sanket Jain /The edge)
Phones rang, pagers rang, doors opened and closed, IV pumps beeped, fans wobbled, and then there was Karl, with a respectful smile, simply and efficiently moving bodies on a stretcher in metal, then covering them with a black tarpaulin.
– Courtney Martin, chief of maternity services at Loma Linda University Medical Center, writes about Karl, a critical worker during the pandemic. Maria L La Ganga helped tell his story in the Los Angeles Times.
To people who have received the 2.51 billion doses of vaccines distributed so far – thank you.
To the more than 177,201,586 people around the world who have tested positive, may your journey to recovery be smooth.
To the families and friends of the 3,836,036 people who have died around the world, including 600,880 in the United States, your loved ones are not forgotten.
Stay safe, everyone.